Ocular Therapeutix, Inc (OCUL): Revenue
$51.95M
Year ended 2025-12-31
$52.05M
Trailing 12 months to 2026-06-30
+0.3%
3-year compound annual growth
+24.4%
5-year compound annual growth
+40.4%
10-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $51.95M | -18.5% | 2026-02-05, From 2025-01-01 |
| 2024-12-31 | $63.72M | +9.0% | 2026-02-05, From 2024-01-01 |
| 2023-12-31 | $58.44M | +13.5% | 2026-02-05, From 2023-01-01 |
| 2022-12-31 | $51.49M | +18.3% | 2025-03-03, From 2022-01-01 |
| 2021-12-31 | $43.52M | +150.1% | 2024-03-11, From 2021-01-01 |
| 2020-12-31 | $17.40M | +311.7% | 2023-03-06, From 2020-01-01 |
| 2019-12-31 | $4.23M | +112.4% | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | $1.99M | +3.5% | 2020-03-12, From 2018-01-01 |
| 2017-12-31 | $1.92M | +1.9% | 2020-03-12, From 2017-01-01 |
| 2016-12-31 | $1.89M | +7.8% | 2019-03-07, From 2016-01-01 |
| 2015-12-31 | $1.75M | +126.7% | 2018-03-08, From 2015-01-01 |
| 2014-12-31 | $772.0K | n/a | 2017-03-10, From 2014-01-01 |
| No annual figure between 2012-12-31 and 2014-12-31. | |||
| 2012-12-31 | $10.0K | n/a | 2015-03-20, From 2012-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Ocular Therapeutix, Inc (OCUL) | 2025-12-31 | $51.95M | -18.5% |
| Q32 Bio Inc. (QTTB) | 2025-12-31 | $53.74M | n/a |
| Agios Pharmaceuticals, Inc. (AGIO) | 2025-12-31 | $54.03M | +48.0% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $49.80M | +60.2% |
| Nektar Therapeutics (NKTR) | 2025-12-31 | $55.23M | -43.9% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $48.47M | -57.7% |
| Aytu Biopharma, Inc (AYTU) | 2026-06-30 | $57.57M | -13.3% |
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | $46.02M | -89.4% |
| Septerna, Inc. (SEPN) | 2025-12-31 | $45.95M | n/m |
Compare OCUL, QTTB, AGIO, LXRX side by side · Screen every company in Pharmaceutical Preparations ↗